GP IIb/IIIa Inhibitors

The Short-Term Aggrastat Infusion Registry (STAIR): Evaluating the Safety and Efficacy of Heparin + Short-Term Tirofiban vs Bivalirudin in PCI

09/05/2019

Joseph Brent Muhlestein , MD, FAHA, FACC;

We compared patients with coronary artery disease who underwent PCI having received either scheduled, planned tirofiban with short-term infusion or planned bivalirudin, which most of the time was without any use of a GP IIb/IIIa receptor...

We compared patients with...

09/05/2019

Cath Lab Digest

Strategies to Circumvent the Delayed Mechanism of Action of Oral Antiplatelets in the Cardiac Catheterization Lab

02/03/2019

Mahir D. Elder , MD, FACC, FSCAI, FASNC, FCCP, RPVI;

The ongoing opioid crisis in this country, along with the judicial use of morphine in patients with acute coronary syndrome, have created an environment where it is important to bring awareness to physicians and medical staff about morphine,...

The ongoing opioid crisis in...

02/03/2019

Cath Lab Digest

The Movement to Short-Infusion Tirofiban in the Cath Lab: the Next Leap in Practice Change

03/01/2018

Joseph Brent Muhlestein , MD, FAHA, FACC;

If patients are not already on dual antiplatelet therapy when they come in, achieving that status is going to take time and there is going to be a window in which they are not protected. One of the advantages of the short-term infusion of...

If patients are not already on...

03/01/2018

Cath Lab Digest

Norton Healthcare Transitions Primary GP IIb/IIIa Inhibitor to Tirofiban

10/01/2017

Divyesh Bhakta , MD;

I have always used a shorter infusion strategy and more recently, have moved to a bolus-only approach for most patients. Reducing the duration of the infusion still preserves the benefit but decreases the bleeding risk.

I have always used a shorter...

10/01/2017

Cath Lab Digest

Ask the Expert

Meta-Analysis: A Look at Three Different GP IIb/IIIa Inhibitors for Anticoagulation During PCI

03/05/2017

Michael J. Lipinski , MD, PhD;

This meta-analysis expands upon prior smaller meta-analyses to enable comparison of each individual GPI with any available anticoagulation strategy for PCI.

This meta-analysis expands upon...

03/05/2017

Cath Lab Digest

The Use of Tirofiban in ACS Patients

10/07/2016

Martin Zenni , MD;

A new, more concentrated format of tirofiban will soon become available to deliver the FDA-approved, high-dose bolus of 25 mcg/kg at the start of treatment: pre-mixed, ready-to-use, 250 mcg/mL in a 15 mL vial.

A new, more concentrated format...

10/07/2016

Cath Lab Digest

Value in the Cath Lab: Contemporary Use of GP IIb/IIIa Inhibitors in the Treatment of ACS at the Mayo Clinic Heath System

07/09/2016

Eric H. Yang , MD;

In terms of choosing which GP IIb/IIIa inhibitor to use, what historically has just been a two-person game, is now a three-person game that includes abciximab, eptifibatide, and tirofiban.

In terms of choosing which GP...

07/09/2016

Cath Lab Digest

Decisions on Glycoprotein IIb/IIIa Inhibitors and the Use of Tirofiban in ACS Patients

03/03/2016

Arnold H. Seto , MD, MPA, CCDS, FACC, FSCAI;

Nothing is more satisfying to an interventional cardiologist than seeing a thrombus disappear before their eyes. This can be achieved with GPIs, especially intracoronary abciximab, but also with thrombus aspiration.

Nothing is more satisfying to an...

03/03/2016

Cath Lab Digest